Quick Answer
Sionna Therapeutics, Inc. reported Stockholders Equity of $306.83 million for fiscal year 2025.
Sionna Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $306.83M | +287.4% |
| 2024 | -$163.71M | -42.5% |
| 2023 | -$114.88M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $321.67M | +316.5% | -4.4% |
| June 30, 2025 | $336.43M | +351.5% | -4.4% |
| March 31, 2025 | $351.77M | +379.0% | +314.9% |
| December 31, 2024 | -$163.71M | -42.5% | -10.2% |
| September 30, 2024 | -$148.55M | — | -11.0% |
| June 30, 2024 | -$133.77M | — | -6.1% |
| March 31, 2024 | -$126.08M | — | -9.8% |
| December 31, 2023 | -$114.88M | — | — |
- Sionna Therapeutics, Inc. showed an increase of +287.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, Sionna Therapeutics, Inc.’s stockholders equity has grown by 367.1% (from -$114.88 million to $306.83 million).
- The most recent figure is from Sionna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: